KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bionano Genomics (BNGO) Revenue (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Revenue for 9 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 2.6% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.5 million through Dec 2025, down 7.37% year-over-year, with the annual reading at $28.5 million for FY2025, 7.37% down from the prior year.
  • Revenue hit $8.0 million in Q4 2025 for Bionano Genomics, up from $7.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $10.7 million in Q4 2023 to a low of $3.2 million in Q1 2021.
  • Historically, Revenue has averaged $7.1 million across 5 years, with a median of $7.3 million in 2022.
  • Biggest five-year swings in Revenue: surged 226.23% in 2021 and later tumbled 34.83% in 2024.
  • Year by year, Revenue stood at $6.3 million in 2021, then soared by 30.36% to $8.2 million in 2022, then soared by 30.51% to $10.7 million in 2023, then dropped by 23.86% to $8.2 million in 2024, then fell by 2.6% to $8.0 million in 2025.
  • Business Quant data shows Revenue for BNGO at $8.0 million in Q4 2025, $7.4 million in Q3 2025, and $6.7 million in Q2 2025.